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84 Pulmosphere™ DPI technology reduces time burden in
cystic ﬁbrosis: the lesson of tobramycin inhalation powder (TIP™)
D.E. Geller1, S. Heuerding2, M. Higgins3, J. Weers4. 1Nemours Children’s Clinic,
Orlando, United States; 2Novartis, Basel, Switzerland; 3Novartis, Horsham, United
Kingdom; 4Novartis, California, United States
Background: CF patients take many inhaled drugs and thus have a large treatment
burden. Dry powder inhalers (DPI) can deliver drugs faster than liquid nebulizers,
but have been limited to low-dose asthma drugs. The T-326 DPI delivers a high
payload of the novel tobramycin PulmoSphere™ formulation, which was developed
to improve the convenience of administration of inhaled tobramycin.
Methods: We review the development of TIP™, the PulmoSphere particle engi-
neering process and the key features and beneﬁts of this novel formulation.
Results: TIP PulmoSphere particles are produced by spray-drying an emulsion-
based feedstock, resulting in small (median diameter: 1.7−2.7mm) spheroidal,
highly porous, sponge-like particles. These characteristics favor dispersibility by
minimizing the area of particle-to-particle contact. The T-326 DPI was designed
to reduce administration time vs nebulization. In two clinical studies (EAGER
and EVOLVE trials), patients with CF 6 years of age with chronic Pseudomonas
aeruginosa and airway obstruction (FEV1 between 25−75% of predicted) were able
to use the drug/device combination successfully. Compared to tobramycin inhalation
solution via jet nebulizer, the TIP/T-326 Inhaler combination provides about a 3-fold
more efﬁcient deposition of tobramycin to the lung, with faster delivery (4−6 vs
15−20min), no thorough cleaning requirement, and greater convenience.
Conclusion: TIP reduces treatment burden and may improve treatment adherence, a
key factor for clinical outcomes in CF. Pulmosphere technology may also be applied
to other drugs (small molecules, peptides, proteins) with applications in CF.
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Objectives: Burk infections cause signiﬁcant morbidity/mortality in CF patients
(pts). Burk-infected CF pts have been excluded from prior aerosolized antibiotic
trials. Aztreonam has in vitro activity vs Burk and there are anecdotal reports of
responses to compassionate use AZLI in Burk-infected pts. A 1 yr randomized
placebo-controlled trial of AZLI, conducted at 35 sites in the US and Canada,
is fully enrolled (ClinicalTrials.gov NCT01059565). Baseline demographic and
microbiology data are presented.
Methods: CF pts 6 yrs with chronic Burk infection (>50% of respiratory cultures
positive in past year, isolate conﬁrmed Burk by reference research lab) and stable
pulmonary disease were enrolled. Pts were randomized to receive 6mos of blinded
AZLI 75mg or placebo TID every day via Pari Investigational eFlow® Nebuliser
System, followed by 6 mos of open label AZLI for all pts. Endpoints include change
in FEV1 and Burk CFU, use of systemic antibiotics and hospitalizations.
Results: 100 pts (males 61%) were randomized and treated. Mean age was 26.3 yrs
(83% >18 yrs). Mean FEV1 57% predicted. B. cenocepacia (42%) and B. multi-
vorans (28%) were the most common of the 9 Burk spp isolated. Pseudomonas
aeruginosa (PA) was isolated in 29% of pts. Mean Burk log10 CFU/gm was 6.9.
Aztreonam MIC50 was 64mg/mL; MIC90 1024mg/mL.
Conclusions: This is the largest randomized controlled trial evaluating the safety
and efﬁcacy of aerosolized antibiotic treatment in Burk-infected CF pts. Baseline
demographics of Burk-infected pts are similar to those of CF pts in PA infection
trials. 70% of Burk-infected pts had either B. cenocepacia and B. multivorans.
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86* Lung function improvement with aztreonam 75mg powder and
solvent for nebuliser solution (AZLI) in a single-arm extension
of a randomized trial of inhaled antipseudomonal antibiotics in
patients with cystic ﬁbrosis (CF) and Pseudomonas aeruginosa
infection
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Objectives: In a 6 month randomized trial of three 28-day on/off courses of
AZLI vs tobramycin nebuliser solution (TNS) in 268 CF patients (pts) with
Pseudomonas aeruginosa (PA) infection, AZLI was superior to TNS at 28 days
and over 3 treatment courses in lung function (FEV1) improvement. A single-arm
extension phase (EXT) evaluated safety and efﬁcacy of AZLI for 3 additional 28-day
on/off treatment cycles (ClinicalTrials.gov NCT00757237). FEV1 responses for the
ﬁrst 2 EXT courses of AZLI are presented.
Methods: CF pts 6 yrs, baseline FEV1 75% predicted, chronic PA and stable
pulmonary disease were enrolled. EXT was open to European pts completing 1
course of AZLI or TNS during the randomized phase (RAND) of the study. The
start of RAND followed 14−28 days off antibiotics. All pts in EXT received AZLI
75mg TID via Pari Investigational eFlow® Nebulizer System for 3 cycles (28 days
on/28 days off). Mean % changes from RAND baseline in FEV1 % predicted at
end of 1st and 2nd EXT course were calculated using observed case data.
Results: Of 174 European pts in RAND, 133 (76%) enrolled in EXT. Mean age
24.7 yrs.
Mean % changes from RAND baseline in FEV1 % predicted:
65 TNS-treated pts after 3 RAND courses: −1.2; Switched to AZLI in EXT course
1 and 2: +4.9 and +4.7 respectively
68 AZLI-treated pts after 3 RAND courses: +8.6; Continued AZLI in EXT course
1 and 2: +6.5 and +5.1 respectively
No new safety issues were noted.
Conclusions: CF pts on AZLI showed sustained FEV1 improvements after each of
5 treatment courses. CF pts showed no FEV1 improvements after 3 courses of TNS
but had marked improvements after switching to AZLI.
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solution) on cystic ﬁbrosis patients with both Staphylococcus
aureus (SA) and Pseudomonas aeruginosa (PA) lung infection
P.A. Flume1, D.E. Geller2, J.S. Loutit3, M.N. Dudley3, D. Conrad4, Mpex 204
Study Group. 1Medical University of South Carolina, Charleston, United States;
2Nemours Children’s Clinic, Orlando, United States; 3Mpex Pharmaceuticals, San
Diego, United States; 4University of California San Diego, San Diego, United
States
Introduction: Approved inhaled antibiotics have been tested in patients with PA
lung infection, but patients frequently have multiple pathogens identiﬁed in sputum
cultures. This study assessed the efﬁcacy of MP-376 in CF patients with chronic
PA lung infection who were also infected with SA at baseline.
Methods: Randomized, double-blind, placebo controlled trial of 3 dose groups
of MP-376 (120mg QD, 240mg QD, 240mg BID) vs. placebo for 28 days,
delivered by a customized investigational PARI eFlow nebulizer. Inclusion criteria:
age 16 years, chronic PA airways infection, FEV1 25−85% predicted, and 3
courses of inhaled antibiotics over the past 12 months. Data for the subset of MITT
patients with SA at baseline were analyzed.
Results: The mean baseline characteristics of the 151 enrolled patients were age
29 years, FEV1 52% of predicted, and 4.8 courses of inhaled antibiotics over last
12 months. Forty-four percent of patients were co-infected with SA (25% with
methicillin-resistant; MRSA) at baseline. The improvement in FEV1 (L) for patients
co-infected with PA and SA for the 240mg BID group (n = 13) compared to placebo
(n = 17) at Day 28 was 11.3% (p = 0.03); the improvement in FEV1 with MP-376
over placebo was similar in the 15 patient subset coinfected with MRSA (15.2%;
p = 0.11).
Conclusion: Nebulized MP-376 demonstrated statistically and clinically signiﬁ-
cant improvement in lung function in this heavily-treated CF patient population,
including patients with both PA and SA lung infection.
